Edesa Biotech, Inc. (EDSA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol EDSA
- Company Edesa Biotech, Inc.
- Price $1.6
- Changes Percentage 77.76
- Change 0.70
- Day Low $0.91
- Day High $1.7
- Year High $2.95
- Year Low $0.72
- Market Cap $13,341,194
- Price Avg 50 EMA (D) $1.36
- Price Avg 200 EMA (D) $1.96
- Exchange NASDAQ
- Volume 62,515,751
- Average Volume 162,901
- Open $1.01
- Previous Close $0.9
- EPS -1.07
- PE -1.49
- Earnings Announcement 2026-05-08 12:00:00
- Shares Outstanding $8,348,160
Company brief: EDESA BIOTECH, INC. (EDSA )
- Healthcare
- Biotechnology
- Dr. Pardeep Nijhawan FRCPC, M.D.
- https://www.edesabiotech.com
- CA
- N/A
- 06-21-2010
- CA27966L3065
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Corporation News
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
globenewswire.com -- TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...